Australia's Sirtex clears U.S. regulatory hurdle for Chinese buyout: Reuters

Liver cancer treatment maker Sirtex Medical (SRX.AX) said on Monday that the U.S. Federal Trade Commission cleared its $1.4 billion buyout by a Chinese consortium, clearing a major hurdle for the deal to go through.